NADMED
The Helsinki-based company developed the first test to measure all four bodily forms of vitamin B3, called NADs, and glutathiones directly from fresh blood in hours to detect vitamin B3 deficiencies and prevent disease.
NADMED has raised €3.5M across 1 funding round from 5 investors, most recently a round in Aug 2024. Based in Helsinki, Finland; active in Healthtech. Data as of 28 Oct 2026.
Helsinki, Finlandwww.nadmed.com ↗
Total raised
€3.5M
€3,500,000
Funding rounds
1
Investors
5
distinct backers
Active since
2024-08
latest 2024-08
Funding by year
EUR raised per yearNADMED — funding by year — interactive chart.
Data table
| NADMED — funding by year | |
|---|---|
| 2024 | €3.5M |
Signals
High confidenceRaise-next likelihood20
base rate 30% for Other
- ▼ Past typical raise window
- ▼ Low backer re-investment
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-08-22 | Other | €3.5M | Business Finland,Nordic Science Investments (NSI),private European investors,University of Helsinki,Voima Ventures | View deal → |
Investors
5Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Iceye€1.5BFinland · Space
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
Global coverage: FundingData